A US biotech has just raised close to AU$100m of funding in a Series A round to advance its viral vector gene therapies for neurological rare disease therapies. Neurogene has four preclinical-stage products in its pipeline and has just presented preliminary, unpublished data in mice studies evaluating the safety and efficacy of its AAV gene therapy in its leading two products.
Some of the funds raised will be allocated to establishing a viral vector manufacturing facility.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)